

CRAFTING



PROSPERITY

Performance Review for the Twelve Months Ended 31st March 2026

It is with great pleasure that I review the performance for Q4 and the full-year ending FY26, both of which represent historic milestones for the Group, with record earnings of Rs. 3.03 Bn in Q4 and Rs. 8.92 Bn for the full year representing year-on-year (YoY) growth of 17.6% and 10.7%, respectively. These results were supported by gross profit margin expansion, reflecting the commercial excellence the Group has delivered through disciplined input cost management and portfolio optimisation.

Before reviewing the Group's performance in detail, it is worth contextualising the operating environment during the period under review. Sri Lanka entered the quarter on solid footing, with GDP growth at 5.0% in calendar year 2025 (CY25) and Q4 CY25 recording a 4.8% YoY expansion, sustaining two years of post-crisis recovery momentum.

Inflation recorded a 2.2% growth YoY end March, with core inflation rising on account of higher transport and housing, electricity, gas, and fuel prices, reflecting the transmission of global commodity price pressures following the Middle East conflict. On the monetary front, the weekly AWPLR rose 34 basis points during the quarter, while market liquidity expanded. Notwithstanding these external headwinds, private sector credit grew at a robust 27% YoY, partly driven by businesses building inventory to circumvent supply chain disruptions but also signalling continued confidence in the domestic economy. The rupee depreciated a further 2% against the US dollar during the quarter, having weakened 5.6% over the full year 2025. Gross official reserves improved to USD 7.0 Bn, supported by multilateral inflows, further strengthening external stability.

Group Performance in Detail

	Quarterly Performance		Annual Performance	
	Q4 FY26	YoY	FY26	YoY
Revenue	Rs. 31,540 Mn	3.9%	Rs. 127,362 Mn	8.0%
Consumer Brands	Rs. 10,545 Mn	4.5%	Rs. 47,027 Mn	2.2%
Healthcare	Rs. 20,409 Mn	3.4%	Rs. 78,009 Mn	11.5%
Mobility	Rs. 563 Mn	15.6%	Rs. 2,293 Mn	17.8%
GP	Rs. 10,889 Mn	16.9%	Rs. 41,428 Mn	11.7%
GP margin	34.5%	3.8%	32.5%	1.1%
EBITDA	Rs 4,915 Mn	11.8%	Rs 16,449 Mn	4.7%
EBITDA margin	15.6%	1.1%	12.9%	(0.4%)
EBIT	Rs 4,337 Mn	13.5%	Rs. 14,145 Mn	3.2%
EBIT margin	13.8%	1.2%	11.1%	(0.5%)
Net finance cost	Rs. 172 Mn	(25.9%)	Rs. 421 Mn	(56.9%)
Earnings	Rs. 3,030 Mn	17.6%	Rs. 8,921 Mn	10.7%
Earnings margin	9.6%	1.1%	7.0%	0.2%

The commentary that follows focuses primarily on quarterly performance, as the FY26 Annual Report available on Hemas' Investor Relations page and the CSE website covers full year performance in detail across the CEO's Review, Group Strategy, and Sector Review sections.

Sector Performance Review

Consumer Brands

Consumer Brands delivered quarterly revenue growth of 4.5% YoY, with an outstanding earnings growth of 27% YoY.

	Quarterly Performance		Annual Performance	
	Q4 FY26	YoY	FY26	YoY
Revenue	Rs 10,545 Mn	4.5%	Rs. 47,027 Mn	2.2%
EBITDA	Rs 1,652 Mn	14.1%	Rs 7,627 Mn	0.1%
EBITDA margin	15.7%	1.3%	16.2%	(0.4%)
Earnings	Rs 1,200 Mn	27.1%	Rs 5,386 Mn	6.5%
Earnings margin	11.4%	2.0%	11.5%	0.5%

Home and Personal Care – Sri Lanka

The Sri Lankan Home and Personal Care industry delivered moderate year-on-year growth. Personal Care, which makes up approximately 45% of the local industry, was the strongest performer, recording double-digit growth of 13% in Q4 and 17% for the full year. Personal Wash and Home Care were broadly flat. Baby Care, spanning both Personal Care and Personal Wash, was the other double-digit growth category, recording 12% quarterly and 13% annually.

Hemas' Home and Personal Care – Sri Lanka delivered a strong quarterly growth of 16.6% YoY, with 97% of that growth volume-led, a compelling indicator of underlying demand. Personal Care, representing 61% of the portfolio, grew 16% YoY during the quarter. Beauty, a strategic priority within the Personal Care category, recorded a growth of 19.5%, largely driven by volume growth. Home Care recovered from its annual drag, recording 11.4% YoY expansion in Q4 driven by volumes. Some portfolio discontinuations also partially influenced the overall growth figure.

Personal Care and Beauty constitute the primary focus of our long-term growth strategy, while Home Care remains a conscious and considered element of our portfolio. Hemas will continue to lead the introduction of global consumer product trends to the local market, tailored with local insights. This value-added proposition will drive the Personal Care category forward, with new formats across several subcategories planned for launch in FY27.

Home and Personal Care – Bangladesh

The Value Added Hair Oil industry in Bangladesh recorded value growth of 3.9% year-to-date as of December 2025, though volumes declined over the same period.

Home and Personal Care – Bangladesh delivered revenue growth of 11% YoY in Q4 and 13% for the full year FY26. Earnings recorded an exceptional increase of over 140% YoY in FY26, though Q4 earnings declined YoY due to higher promotional activity during the period, but within budgeted expectations. Margins expanded, driven by an improved sales mix favouring higher-margin products, complemented by effective cost price controls.

Looking ahead, Home and Personal Care – Bangladesh will define its growth trajectory through new category development, leveraging its extensive distribution network to drive sustained profitability.

Learning

The school season shift resulted in revenue and volume contraction for Atlas Axillia in Q4 FY26 relative to Q4 FY25. However, the newer portfolio verticals *Back to School* and *EduToys* recorded significant volume growth during this period. The book, pen, and pencil categories also gained market share during the quarter. The next school-based seasonal uplift is expected in Q3 FY27; in the interim, focus will be directed toward developing the broader portfolio to sustain profitability.

Distribution optimisation is driving meaningful uptake of higher-value ranges, particularly within Back to School and EduToys, with early results encouraging. As market leader in learning, Atlas continues to champion e-learning in Sri Lanka, leading the evolution toward technology-enabled educational experiences.

Healthcare

Revenue growth of 3.4% translated into earnings growth of 9.3% in Q4; a compelling demonstration of margin leverage in the Healthcare segment performance.

	Quarterly Performance		Annual Performance	
	Q4 FY26	YoY	FY26	YoY
Revenue	Rs 20,409 Mn	3.4%	Rs. 78,009 Mn	11.5%
EBITDA	Rs 2,834 Mn	18.0%	Rs. 8,633 Mn	13.7%
EBITDA margin	13.9%	1.7%	11.1%	0.2%
Earnings	Rs 1,688 Mn	9.3%	Rs 4,907 Mn	14.2%
Earnings margin	8.3%	0.5%	6.3%	0.1%

Pharmaceutical Distribution

The private pharmaceutical market in Sri Lanka grew 6.7% in volume and 8.7% in value in the quarter ending December 2025. Hemas Pharma maintained its substantial market leadership during the quarter.

Hemas Pharmaceuticals saw Q4 FY26 revenue broadly flat relative to Q4 FY25. While the quarter remained profitable, YoY earnings growth was marginally negative due to a higher tax charge in Q4 FY26. On a full-year basis, however, both revenue and earnings recorded YoY growth.

New product approvals during the quarter continue to support the pipeline for future periods. Distribution re-engineering and digitalisation are expected to drive further margin improvement, while the consumer wellness portfolio is being actively scaled as an additional profitability driver.

Pharmaceutical Manufacturing

For the twelve months to December 2025, the private pharmaceutical market recorded value growth of 9.6% YoY, volume growth of 8% YoY, and a market value of Rs. 113 Bn. Against this backdrop, Hemas' pharmaceutical manufacturing arm, Morison, delivered a strong performance for the twelve months ending March 2026, achieving volume growth of 18.6% in pharma manufacturing.

Morison advanced its value market share ranking to #23 in the total private pharmaceutical market by end December 2025, gaining 14 positions from the previous year, while holding its volume market share at #2, reflecting continued and broad-based growth across the business. The business now generates 75% of its revenue from manufacturing pharmaceuticals and OTC products, while generating the rest from diagnostics. In FY26, Morison discontinued its import and distribution of pharmaceuticals and transferred it within the Group for better focus and strategic fit. Post divestment of the distributed pharma agencies, Morison recorded earnings growth in excess of 100% YoY in FY26 across its manufactured and diagnostics portfolios.

As the first local manufacturer to introduce Empagliflozin, Cilnidipine, and Rivaroxaban in Sri Lanka, which are all latest-generation therapies in diabetes and cardiology, Morison has redefined the capabilities of local pharmaceutical manufacturing. Within just two years of launch, the Empagliflozin brand EmpaMor has grown to command a market-leading position in volumes, while the newer cardiology range, which includes CilniMor, BisoMor, and RivoMor, is gaining meaningful traction across the market.

Looking ahead, Morison is actively pursuing export opportunities, with the EU-GMP certification currently underway, a significant step that will open access to international markets.

Hospitals

Hemas Hospitals delivered revenue growth of 24% in FY26, driven by volume growth across all services. This momentum continued in Q4 FY26, with total admissions increasing year-on-year, supported by a 19% growth in surgical admissions. Over the first three quarters of FY26, Hemas Hospitals recorded revenue growth of 26%, significantly outpacing the listed hospital industry.

Looking ahead, the Liver Program's growing caseload is emerging as a meaningful near-term driver of revenue and earnings, reflecting Hemas Hospitals' broader push to scale capabilities across high-demand specialties. This clinical ambition is underpinned by a strategic focus on establishing Hemas Hospitals as a digitally mature, insight-driven healthcare brand. A key pillar of the Group's longer-term capital allocation and growth plan, the Thalawathugoda facility expansion is advancing with purpose. Groundbreaking is now complete, regulatory engagement is actively underway, and the facility is targeted to begin contributing to revenue in 2029.

Mobility

Mobility delivered a strong performance with revenue growth in both Q4 and FY26, though Q4 earnings were impacted by the Middle East crisis, which had an immediate and meaningful effect on the aviation segment.

	Quarterly Performance		Annual Performance	
	Q4 FY26	YoY	FY26	YoY
Revenue	Rs 563 Mn	15.6%	Rs. 2,293 Mn	17.8%
EBITDA	Rs 423 Mn	(0.2%)	Rs. 1,599 Mn	4.4%
EBITDA margin	75.1%	(11.9%)	69.7%	(8.9%)
Earnings	Rs 227 Mn	(15.0%)	Rs. 861 Mn	6.1%
Earnings margin	40.3%	(14.5%)	37.5%	(4.1%)

Within Maritime, Evergreen recorded exceptional Q4 TEU volume growth of 44% against an industry growth of 10%, reflecting both the depth of Hemas' principal relationships and Colombo's growing prominence as a regional transshipment hub.

Intensified competition and geopolitical disruptions, most notably the Middle East conflict's impact on passenger volumes and network capacity toward end FY26, made for a more challenging year in Aviation. Forbes Air Services recorded a quarterly revenue decline of 17% YoY, though the full-year earnings growth remained marginally positive. Emirates maintained air cargo market leadership, ranking second in passenger market share across operated routes.

Mobility is well positioned to capitalise on the growth in regional trade and travel, supported by Sri Lanka's rising relevance as a neutral Indian Ocean logistics and maritime services hub and strong principal relationships that provide a foundation for further expansion. Particular emphasis

will be placed on growing maritime support services, including ship spare logistics, crew logistics, and outer harbour services, to strengthen the core agency business while focusing on high-potential adjacencies in regional logistics to capture value from evolving regional trade dynamics, leveraging Sri Lanka's strategic positioning.

Sustainability

The Group continued to advance its sustainability agenda during the quarter, delivering steady progress across environmental priorities and social impact. These efforts support long-term resilience, regulatory readiness, and the Group's position as a purpose-led organization.

Cumulative plastic recovery reached over 2.9 million kilograms, reflecting continued progress towards the Group's commitments to recover 50% of plastic placed on the market by 2025 and 100% by 2030, and positioning the Group to meet upcoming Extended Producer Responsibility (EPR) requirements.

Water intensity increased marginally from 1.5m³ to 1.6m³, compared to Q4 of FY25 highlighting the need for continued focus on efficiency across operations. In response, targeted efficiency and conservation initiatives are being accelerated across key operations to mitigate resource risk, avoid potential cost escalation, and strengthen long-term water security.

Renewable energy adoption reached 11.1% of total electricity consumption, marking continued progress towards the Group's goal of 25% renewable energy. Further opportunities being pursued to optimize energy sourcing, improve cost stability, and reduce carbon exposure over the medium term.

The Group continued to deliver social impact across education, health and wellbeing, and inclusion, reaching over 28,900 individuals during the quarter. These initiatives support community engagement and help maintain the Group's license to operate in communities the business operates in.

Sustainability priorities continue to be embedded into business decision-making and operational performance across sectors, with a near-term focus on accelerating renewable energy adoption, improving water efficiency in high-risk locations, and scaling post-consumer waste recovery to meet 2030 commitments.

Strategy and Outlook

Post quarter, inflation rose further to 5.4% in April as commodity price increases filtered through the economy, driven primarily by higher transportation and housing, water, electricity, and fuel costs. While the Middle East conflict is expected to exert some pressure on the balance of payments through higher fuel import costs and softer tourism receipts, continued growth in

remittances, bilateral and multilateral inflows, and anticipated IMF disbursements are expected to provide meaningful buffers and soften the overall impact on the Sri Lankan economy. Periodic price increases across the portfolio are anticipated as commodity cost and exchange rate pressures transmit to consumer prices.

Importantly, Sri Lanka's recent crisis experience has built real institutional and corporate resilience, and Hemas is no exception. The Group enters FY27 stronger, sharper, and ready to grow. The FY30 Long Range Plan, anchored around USD 100 Mn in investments over the next four years, sets an ambitious course, with internationalisation and adjacency growth as its two defining themes. The Group is also actively exploring entry into an additional business vertical during this period, further broadening its platform for long-term value creation.



Ashish Chandra

Group CEO

May 22, 2026

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

	Three Months Ended 31 March			Twelve Months Ended 31 March		
	2026	2025	Change %	2026	2025	Change %
Revenue from Contracts with Customers	31,540,250	30,347,241	3.9%	127,361,997	117,970,174	8.0%
Cost of Sales	(20,651,100)	(21,029,611)	-1.8%	(85,934,263)	(80,896,885)	6.2%
Gross Profit	10,889,150	9,317,630	16.9%	41,427,734	37,073,289	11.7%
Other Operating Income	354,886	465,033	-23.7%	893,104	1,092,243	-18.2%
Selling and Distribution Expenses	(2,729,280)	(2,464,331)	10.8%	(10,656,465)	(9,675,474)	10.1%
Administrative Expenses	(4,529,905)	(3,787,672)	19.6%	(17,841,396)	(15,235,236)	17.1%
Share of Results of Equity Accounted Investees (Net of Tax)	352,129	289,112	21.8%	321,587	451,807	-28.8%
Operating Profit	4,336,980	3,819,772	13.5%	14,144,564	13,706,629	3.2%
Finance Cost	(353,284)	(354,872)	-0.4%	(1,025,729)	(1,504,274)	-31.8%
Finance Income	181,017	122,386	47.9%	604,385	526,447	14.8%
Profit Before Tax	4,164,713	3,587,286	16.1%	13,723,220	12,728,802	7.8%
Income Tax Expense	(1,032,139)	(944,700)	9.3%	(4,431,055)	(4,390,141)	0.9%
Profit for the Period	3,132,574	2,642,586	18.5%	9,292,165	8,338,661	11.4%
Attributable to:						
Equity Holders of the Parent	3,029,539	2,576,438	17.6%	8,920,688	8,056,961	10.7%
Non-Controlling Interests	103,035	66,148	55.8%	371,477	281,700	31.9%
	3,132,574	2,642,586	18.5%	9,292,165	8,338,661	11.4%

	LKR	LKR	LKR	LKR
Earnings Per Share				
Basic	1.01	0.90	2.98	2.70
Diluted	1.00	0.90	2.97	2.70
Dividend Per Share	-	-	0.95	4.00

*Dividend per share for 2026 is presented after the 1:5 share split.

All values are in LKR'000, unless otherwise stated.

The above figures are provisional and subject to audit.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	Three Months Ended 31 March		Twelve Months Ended 31 March	
	2026	2025	2026	2025
Profit for the Period	3,132,574	2,642,586	9,292,165	8,338,661
Other Comprehensive Income				
Other Comprehensive Income to be Reclassified to Profit or Loss in Subsequent Periods (Net of Tax)				
Exchange Differences on Translation of Foreign Operations	(2,625)	6,830	13,056	(74,604)
Share of Other Comprehensive Profit/ (Loss) of Equity Accounted Investees (Cash Flow Hedge)	(23,041)	57,557	(23,041)	57,557
	(25,666)	64,387	(9,985)	(17,047)
Other Comprehensive Income not to be Reclassified to Profit or Loss in Subsequent Periods (Net of Tax)				
Net Profit /(Loss) on Financial Assets at FVOCI (Equity)	(34,885)	(16,609)	(9,959)	23,519
Actuarial Loss on Defined Benefit Plans	(174,256)	(30,405)	(174,256)	(30,405)
Revaluation of Land and Building	756,383	808,515	756,383	808,515
Share of Other Comprehensive Income of Joint Venture / Associates	344,255	170,103	344,255	170,103
	891,497	931,604	916,423	971,732
Other Comprehensive Income for the Period, Net of Tax	865,831	995,991	906,438	954,685
Total Comprehensive Income for the Period, Net of Tax	3,998,405	3,638,577	10,198,603	9,293,346
Attributable to:				
Equity Holders of the Parent	3,884,018	3,557,854	9,815,774	8,997,071
Non-Controlling Interests	114,387	80,723	382,829	296,275
	3,998,405	3,638,577	10,198,603	9,293,346

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 31 March	
	2026	2025
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	25,966,682	24,396,797
Investment Properties	4,415,106	4,305,782
Right-of-Use Assets	2,003,920	1,889,329
Intangible Assets	3,480,054	3,333,057
Investment in Equity Accounted Investees	2,786,257	2,153,877
Lease Receivables	2,635	22,648
Other Non-Current Financial Assets	301,930	254,797
Deferred Tax Asset	185,512	228,746
	39,142,096	36,585,033
Current Assets		
Inventories	23,006,773	21,182,560
Trade and Other Receivables	26,417,903	25,971,470
Tax Recoverable	308,422	301,130
Lease Receivables	14,897	15,369
Other Current Financial Assets	177,958	183,326
Cash and Cash Equivalents	17,783,292	12,578,510
	67,709,245	60,232,365
Assets Held for Sale	11,013	73,128
Total Assets	106,862,354	96,890,526
EQUITY AND LIABILITIES		
Equity		
Stated Capital	7,989,306	7,824,276
Other Capital and Revenue Reserves	139,808	75,567
Other Components of Equity	9,539,638	8,471,295
Retained Earnings	39,342,550	33,409,249
Equity Attributable to Equity Holders of the Parent	57,011,302	49,780,387
Non-Controlling Interests	716,165	540,045
Total Equity	57,727,467	50,320,432
Non-Current Liabilities		
Interest-Bearing Loans and Borrowings	3,469,021	4,617,055
Other Non-Current Financial Liabilities	275,575	275,375
Deferred Tax Liability	4,094,685	3,473,577
Employee Benefit Liability	1,917,604	1,561,558
	9,756,885	9,927,565
Current Liabilities		
Trade and Other Payables	33,618,719	31,940,411
Income Tax Liabilities	1,692,826	1,440,936
Interest-Bearing Loans and Borrowings	2,676,904	2,939,338
Bank Overdraft	1,387,532	317,185
	39,375,981	36,637,870
Liabilities Associated with Assets Held for Sale	2,021	4,659
Total Equity and Liabilities	106,862,354	96,890,526
Net Assets per share - (LKR)	19.03	16.67

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

These financial statements are in compliance with the requirements of the Companies Act No. 07 of 2007.


Moiz Rehmanjee

Group Chief Financial Officer

The Board of Directors is responsible for these financial statements.
Signed for and on behalf of the Board by,


Ajith Fernando

Chairman
Colombo
May 22, 2026


Ashish Chandra

Group Chief Executive Officer

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Attributable to Equity Holders of the Parent						Retained Earnings	Total	Non - Controlling Interests	Total Equity
	Stated Capital	Other Capital & Revenue Reserves	Revaluation Reserve	Foreign Currency Translation Reserve	Other Component of Equity Fair Value Reserve of Financial Assets at FVOCI	Cash Flow Hedge Reserve				
As at 1 April 2024	7,783,875	103,084	7,721,486	409,292	(44,052)	(585,483)	28,043,567	43,431,769	687,829	44,119,598
Profit for the Period	-	-	-	-	-	-	8,056,961	8,056,961	281,700	8,338,661
Other Comprehensive Income	-	-	963,580	(74,604)	23,519	57,557	(29,942)	940,110	14,575	954,685
Total Comprehensive Income	-	-	963,580	(74,604)	23,519	57,557	8,027,019	8,997,071	296,275	9,293,346
Share Based Payments	-	(10,474)	-	-	-	-	-	(10,474)	-	(10,474)
Exercise of ESOS	40,401	-	-	-	-	-	-	40,401	-	40,401
Transfer Due to the Expiry of ESOS	-	(17,043)	-	-	-	-	17,043	-	-	-
Final Dividend - 2023/24	-	-	-	-	-	-	(1,790,719)	(1,790,719)	-	(1,790,719)
Interim Dividend - 2024/25	-	-	-	-	-	-	(597,181)	(597,181)	-	(597,181)
Subsidiary Dividend to Non-Controlling Interest	-	-	-	-	-	-	-	-	(46,009)	(46,009)
Adjustment in Respect of Changes in Group Holding	-	-	-	-	-	-	(290,480)	(290,480)	(398,050)	(688,530)
As at 31 March 2025	7,824,276	75,567	8,685,066	334,688	(20,533)	(527,926)	33,409,249	49,780,387	540,045	50,320,432
As at 1 April 2025	7,824,276	75,567	8,685,066	334,688	(20,533)	(527,926)	33,409,249	49,780,387	540,045	50,320,432
Profit for the Period	-	-	-	-	-	-	8,920,688	8,920,688	371,477	9,292,165
Other Comprehensive Income	-	-	1,088,287	13,056	(9,959)	(23,041)	(173,257)	895,086	11,352	906,438
Total Comprehensive Income	-	-	1,088,287	13,056	(9,959)	(23,041)	8,747,431	9,815,774	382,829	10,198,603
Share Based Payments	-	64,241	-	-	-	-	-	64,241	-	64,241
Exercise of ESOS	165,030	-	-	-	-	-	-	165,030	-	165,030
Forfeiture of unclaimed dividends	-	-	-	-	-	-	23,271	23,271	-	23,271
Final Dividend -2024/25	-	-	-	-	-	-	(2,090,576)	(2,090,576)	-	(2,090,576)
Interim Dividend - 2025/26	-	-	-	-	-	-	(746,825)	(746,825)	-	(746,825)
Subsidiary Dividend to Non-Controlling Interest	-	-	-	-	-	-	-	-	(206,709)	(206,709)
As at 31 March 2026	7,989,306	139,808	9,773,353	347,744	(30,492)	(550,967)	39,342,550	57,011,302	716,165	57,727,467

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

COMPANY STATEMENT OF PROFIT OR LOSS

	Three Months Ended 31 March			Twelve Months Ended 31 March		
	2026	2025	Change %	2026	2025	Change %
Revenue from Contracts with Customers	786,795	546,821	43.9%	2,324,743	1,605,874	44.8%
Cost of Sales	-	-	-	-	-	-
Gross Profit	786,795	546,821	43.9%	2,324,743	1,605,874	44.8%
Other Operating Income	176,356	1,459,253	-87.9%	2,614,270	3,701,606	-29.4%
Administrative Expenses	(466,774)	(460,059)	1.5%	(2,111,847)	(1,887,806)	11.9%
Operating Profit	496,377	1,546,015	67.9%	2,827,166	3,419,674	-17.3%
Finance Cost	(79,611)	(78,338)	1.6%	(257,847)	(261,344)	-1.3%
Finance Income	6,752	1,990	239.3%	7,784	4,459	74.6%
Profit Before Tax	423,518	1,469,667	71.2%	2,577,103	3,162,789	-18.5%
Income Tax Expense	6,157	(12,901)	147.7%	(19,489)	(69,469)	71.9%
Profit for the Period	429,675	1,456,766	70.5%	2,557,614	3,093,320	-17.3%

COMPANY STATEMENT OF COMPREHENSIVE INCOME

	Three Months Ended 31 March		Twelve Months Ended 31 March	
	2026	2025	2026	2025
Profit for the Period	429,675	1,456,766	2,557,614	3,093,320
Other Comprehensive Income				
Actuarial Gain/ (Loss) on Defined Benefit Plans	(5,608)	(3,281)	(5,608)	(3,281)
Net Gain/ (Loss) on Financial Assets at FVOCI	(7,426)	(2,739)	(2,226)	4,143
Other Comprehensive Income for the Period, Net of Tax	(13,034)	(6,020)	(7,834)	862
Total Comprehensive Income for the Period, Net of Tax	416,641	1,450,746	2,549,780	3,094,182

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

COMPANY STATEMENT OF FINANCIAL POSITION

	As at 31 March	
	2026	2025
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	71,009	82,544
Investment Properties	1,300,098	1,260,522
Right-of-Use Assets	85,887	-
Intangible Assets	26,204	30,712
Investment in Subsidiaries	19,261,726	19,116,227
Other Non-Current Financial Assets	25,784	21,322
	20,770,708	20,511,327
Current Assets		
Trade and Other Receivables	793,820	562,781
Tax Recoverable	37,387	33,005
Other Current Financial Assets	3,514	23,455
Cash and Cash Equivalents	1,469,981	84,078
	2,304,702	703,318
Total Assets	23,075,410	21,214,646
EQUITY AND LIABILITIES		
Equity		
Stated Capital	7,989,306	7,824,276
Other Capital and Revenue Reserves	361,159	296,918
Other Components of Equity	4,762	6,988
Retained Earnings	9,275,810	9,548,151
Total Equity	17,631,037	17,676,333
Non-Current Liabilities		
Interest-Bearing Loans and Borrowings	173,000	346,000
Deferred Tax Liability	313,257	296,172
Employee Benefit Liability	69,708	58,572
	555,965	700,744
Current Liabilities		
Trade and Other Payables	1,139,119	931,090
Interest-Bearing Loans and Borrowings	3,197,197	1,842,217
Bank Overdraft	552,092	64,262
	4,888,408	2,837,569
Total Equity and Liabilities	23,075,410	21,214,646
Net Assets per share - (LKR)	5.88	5.92

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

These financial statements are in compliance with the requirements of the Companies Act No. 07 of 2007.



Moiz Rehmanjee
Group Chief Financial Officer

The Board of Directors is responsible for these financial statements.
Signed for and on behalf of the Board by,



Ajith Fernando
Chairman
Colombo
May 22, 2026



Ashish Chandra
Group Chief Executive Officer

COMPANY STATEMENT OF CHANGES IN EQUITY

	Stated Capital	Other Capital Reserves	Other Components Of Equity	Retained Earnings	Total Equity
			Fair Value Reserve of Financial Assets at FVOCI		
As at 1 April 2024	7,783,875	324,435	2,845	8,828,968	16,940,123
Profit for the Period	-	-	-	3,093,320	3,093,320
Other Comprehensive Income	-	-	4,143	(3,281)	862
Total Comprehensive Income	-	-	4,143	3,090,039	3,094,182
Share Based Payments	-	(10,474)	-	-	(10,474)
Exercise of share options	40,401	-	-	-	40,401
Transfer due to the Expiry of ESOS	-	(17,043)	-	17,043	-
Final Dividend - 2023/24	-	-	-	(1,790,719)	(1,790,719)
Interim Dividend - 2024/25	-	-	-	(597,181)	(597,181)
As at 31 March 2025	7,824,276	296,918	6,988	9,548,151	17,676,333
As at 1 April 2025	7,824,276	296,918	6,988	9,548,151	17,676,333
Profit for the Period	-	-	-	2,557,614	2,557,614
Other Comprehensive Income	-	-	(2,226)	(5,608)	(7,834)
Total Comprehensive Income	-	-	(2,226)	2,552,006	2,549,780
Share Based Payments	-	64,241	-	-	64,241
Exercise of share options	165,030	-	-	-	165,030
Dividend payable reversal	-	-	-	13,054	13,054
Final Dividend -2024/25	-	-	-	(2,090,576)	(2,090,576)
Interim Dividend - 2025/26	-	-	-	(746,825)	(746,825)
As at 31 March 2026	7,989,306	361,159	4,762	9,275,810	17,631,037

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

STATEMENT OF CASH FLOWS

Twelve Months Ended 31 March	Group		Company	
	2026	2025	2026	2025
Operating Activities				
Profit Before Taxation	13,723,220	12,728,802	2,577,103	3,162,789
Adjustments for,				
Depreciation and impairment of Property, Plant and Equipment	1,827,946	1,588,743	25,595	30,870
Amortisation of Right-of-Use Assets	414,632	339,675	85,887	70,742
(Gain)/ Loss on Disposal of Property, Plant and Equipment, Investment Properties, Intangible Assets	(47,873)	(48,283)	(13,805)	(8)
Gain on Fair Value Adjustment of Investment Properties	(106,398)	(252,681)	(39,577)	(117,522)
Amortisation and impairment of Intangible Assets	121,762	69,266	6,290	8,501
Provision/ (Reversal) for Obsolete & Slow-moving Stocks	(50,544)	(616,135)	-	-
Provision/(Reversal) for Impairment of Trade and Other Receivables	80,505	(113,239)	(34,383)	10,048
Provision/(Reversal) for Share Based Payment Expense	92,706	(4,562)	34,473	1,257
(Gain) / Loss on termination of leases	(2,557)	(83,556)	-	-
Finance Cost	1,025,729	1,504,274	257,847	261,344
Finance Income	(604,385)	(526,447)	(7,784)	(4,459)
Investment Income	(59)	-	(2,552,365)	(3,574,024)
Share of Results of Equity Accounted Investees (Net of Tax)	(321,587)	(451,807)	-	-
Provision for Employee Benefit Liability	299,552	303,311	15,593	11,498
Operating Cash Flows before Working Capital Changes	16,452,650	14,437,361	354,874	(138,964)
Working Capital Adjustments				
(Increase)/Decrease in Inventories	(1,773,669)	2,208,720	-	-
(Increase)/Decrease in Trade and Other Receivables	(461,895)	483,160	(138,392)	(136,898)
Increase/(Decrease) in Trade and Other Payables	1,698,941	1,092,758	219,043	167,880
Increase/(Decrease) in Other Non-Current Financial Liabilities	200	(4,130)	-	-
Cash Generated from Operations	15,916,227	18,217,869	435,525	(107,983)
Finance Cost Paid	(752,914)	(1,264,594)	(247,202)	(253,248)
Finance Income Received	591,460	501,716	7,754	4,293
Income Tax Paid	(3,762,856)	(3,905,812)	(4,380)	(32,589)
Employee Retirement Benefit Paid	(183,906)	(161,210)	(10,428)	(2,336)
Net Cash Flows From/(Used in) Operating Activities	11,808,011	13,387,969	181,269	(391,862)
Investing Activities				
Purchase of Property, Plant and Equipment	(2,409,354)	(5,080,094)	(14,060)	(26,545)
Investment in Intangible Assets	(267,150)	(115,845)	(1,783)	(18,130)
Acquisition of /Investment in Subsidiaries	-	-	(145,500)	(844,680)
Acquisition of /Investment in Equity Accounted Investees	(190,001)	-	-	-
Net Change in Financial Assets	(44,173)	(1,791)	13,253	298,400
Dividend received from Equity Accounted Investees	200,422	-	-	-
Investment Income Received	59	-	2,552,365	3,574,024
Proceeds on Disposal of Property, Plant and Equipment/ Intangible Assets	71,699	188,350	13,805	8
Net Cash Flows From/(Used in) Investing Activities	(2,638,498)	(5,009,380)	2,418,080	2,983,078
Financing Activities				
Interest-Bearing Loans and Borrowings (Net)	(2,148,167)	(4,763,854)	999,560	(52,107)
Proceed from Exercise of ESOS	136,565	34,489	136,565	34,489
Proceeds from/to Non-Controlling Interest	-	(688,530)	-	-
Dividends Paid to Equity Holders of the Parent	(2,837,401)	(2,387,900)	(2,837,401)	(2,387,900)
Dividends Paid to Non-Controlling Interest	(206,709)	(46,009)	-	-
Net Cash Flows From/(Used in) Financing Activities	(5,055,712)	(7,851,804)	(1,701,276)	(2,405,518)
Net Increase/(Decrease) in Cash and Cash Equivalents	4,113,801	526,785	898,073	185,698
Net Foreign Exchange Difference	20,634	(78,044)	-	-
Cash and Cash Equivalents at the Beginning of the Period	12,261,325	11,812,583	19,816	(165,882)
Cash and Cash Equivalents at the End of the Period	16,395,760	12,261,325	917,889	19,816

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

SEGMENTAL INFORMATION

Three Months Ended 31 March	Consumer Brands		Healthcare		Mobility		Others		Group	
	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025
Continuing Operation										
Revenue from Contract with Customers										
Segmental Revenue - Gross	10,602,074	10,150,168	22,401,756	21,872,808	580,912	499,154	935,013	683,629	34,519,755	33,205,759
Intra Segmental Revenue	(57,050)	(63,040)	(1,993,096)	(2,126,650)	(18,086)	(12,201)	(65,576)	(62,868)	(2,133,808)	(2,264,759)
Segment Revenue	10,545,024	10,087,128	20,408,660	19,746,158	562,826	486,953	869,437	620,761	32,385,947	30,941,000
Inter Segmental Revenue	-	-	-	-	-	-	(845,696)	(593,759)	(845,697)	(593,759)
Total Revenue from Contract with Customers	10,545,024	10,087,128	20,408,660	19,746,158	562,826	486,953	23,741	27,002	31,540,250	30,347,241
Results										
Segmental Results	1,428,093	1,232,882	2,441,853	2,108,442	358,170	323,746	(349,663)	(387,091)	3,878,453	3,277,979
Finance Cost	(69,133)	(102,011)	(189,311)	(224,416)	(2,559)	3,675	(92,281)	(32,120)	(353,284)	(354,872)
Finance Income	94,802	63,514	32,958	43,198	37,918	18,688	15,339	(3,014)	181,017	122,386
Change in Fair Value of Investment Properties	325	800	-	-	45,610	101,850	60,463	150,031	106,398	252,681
Share of Results of Equity Accounted Investees (Net of Tax)	(2,541)	-	-	-	6,360	(7,835)	348,311	296,947	352,129	289,112
Profit/(Loss) before Tax	1,451,546	1,195,185	2,285,500	1,927,224	445,499	440,124	(17,832)	24,753	4,164,713	3,587,286
Income Tax	(252,465)	(246,994)	(577,844)	(371,835)	(133,934)	(122,031)	(67,896)	(203,841)	(1,032,138)	(944,700)
Profit/(Loss) for the Period	1,199,081	948,191	1,707,656	1,555,389	311,565	318,094	(85,728)	(179,088)	3,132,574	2,642,586
Attributable to:										
Equity Holders of the Parent	1,200,471	944,331	1,688,133	1,544,463	226,664	266,731	(85,728)	(179,088)	3,029,539	2,576,438
Non-Controlling Interests	(1,390)	3,860	19,524	10,926	84,901	51,362	-	-	103,035	66,148
	1,199,081	948,191	1,707,656	1,555,389	311,565	318,094	(85,728)	(179,088)	3,132,574	2,642,586

All values are in LKR'000, unless otherwise stated.

The above figures are provisional and subject to audit.

SEGMENTAL INFORMATION

Twelve Months Ended 31 March	Consumer Brands		Healthcare		Mobility		Others		Group	
	2026	2025	2026	2025	2026	2025	2026	2025	2026	2025
Continuing Operation										
Revenue from Contract with Customers										
Segmental Revenue - Gross	47,208,641	46,192,452	86,066,256	76,155,152	2,344,966	1,992,586	2,902,197	2,133,417	138,522,060	126,473,607
Intra Segmental Revenue	(182,126)	(194,825)	(8,057,704)	(6,167,906)	(51,832)	(45,523)	(249,068)	(243,856)	(8,540,730)	(6,652,110)
Segment Revenue	47,026,515	45,997,627	78,008,552	69,987,246	2,293,134	1,947,063	2,653,129	1,889,561	129,981,330	119,821,497
Inter Segmental Revenue	-	-	-	-	-	-	(2,619,333)	(1,851,323)	(2,619,333)	(1,851,323)
Total Revenue from Contract with Customers	47,026,515	45,997,627	78,008,552	69,987,246	2,293,134	1,947,063	33,796	38,238	127,361,997	117,970,174
Results										
Segmental Results										
Finance Cost	(209,293)	(326,035)	(647,103)	(981,794)	(9,441)	(34,938)	(159,892)	(161,507)	(1,025,729)	(1,504,274)
Finance Income	293,099	238,325	157,183	223,883	136,099	63,849	18,004	390	604,385	526,447
Change in Fair Value of Investment Properties	325	800	-	-	45,610	101,850	60,463	150,031	106,398	252,681
Share of Results of Equity Accounted Investees (Net of Tax)	(5,963)	-	-	-	20,834	146,156	306,716	305,651	321,587	451,807
Profit/(Loss) before Tax	6,915,324	6,829,881	6,769,524	5,762,875	1,688,178	1,517,841	(1,649,806)	(1,381,796)	13,723,220	12,728,802
Income Tax	(1,526,726)	(1,764,737)	(1,822,632)	(1,398,046)	(498,441)	(498,115)	(583,256)	(729,244)	(4,431,055)	(4,390,141)
Profit/(Loss) for the Period	5,388,598	5,065,144	4,946,892	4,364,829	1,189,737	1,019,727	(2,233,062)	(2,111,040)	9,292,165	8,338,661
Attributable to:										
Equity Holders of the Parent	5,386,379	5,059,101	4,906,558	4,297,332	860,813	811,567	(2,233,062)	(2,111,040)	8,920,688	8,056,961
Non-Controlling Interests	2,219	6,043	40,334	67,497	328,924	208,160	-	-	371,477	281,700
	5,388,598	5,065,144	4,946,892	4,364,829	1,189,737	1,019,727	(2,233,062)	(2,111,040)	9,292,165	8,338,661

All values are in LKR'000, unless otherwise stated.

The above figures are provisional and subject to audit.

SEGMENTAL INFORMATION

As at	Consumer Brands		Healthcare		Mobility		Others		Group	
	31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025
ASSETS										
Non-Current Assets										
Property, Plant and Equipment	6,965,065	6,460,433	15,040,308	13,943,192	52,251	59,630	738,783	793,812	22,796,407	21,257,067
Right of Use Assets	503,345	431,575	1,562,496	1,418,410	107,250	1,246	99,109	38,096	2,272,200	1,889,327
Investment Property	3,325	3,000	-	-	1,486,960	1,441,350	6,327,609	6,166,205	7,817,894	7,610,555
Other Non Current Financial Assets	41,559	40,613	928,527	134,197	4,958	-	165,211	103,022	1,140,255	277,832
Other Non Current Assets	6,353,872	6,230,847	2,592,907	1,738,254	1,224,702	1,436,381	27,477,004	27,942,427	37,648,484	37,347,909
Segmental Non Current Assets	13,867,166	13,166,468	20,124,238	17,234,053	2,876,121	2,938,607	34,807,715	35,043,562	71,675,240	68,382,690
Deferred Tax Assets									185,512	228,746
Eliminations/Adjustments									(32,718,656)	(32,026,403)
Total Non Current Assets	13,867,166	13,166,468	20,124,238	17,234,053	2,876,121	2,938,607	34,807,715	35,043,562	39,142,096	36,585,033
Current Assets										
Other Current Financial Assets	2,395,729	1,366,832	111,036	788,110	76,790	12,973	556,299	535,941	3,139,854	2,703,856
Segmental Current Assets	22,720,965	19,400,865	39,652,642	36,793,287	5,618,037	5,399,973	3,465,071	986,906	71,456,715	62,581,031
Tax Recoverable									308,422	301,130
Eliminations/Adjustments									(7,195,747)	(5,353,652)
Total Current Assets	25,116,694	20,767,697	39,763,677	37,581,397	5,694,828	5,412,946	4,021,371	1,522,847	67,709,245	60,232,365
Assets Held for Sale	11,013	73,128							11,013	73,128
Total Assets	38,994,873	34,007,293	59,887,916	54,815,450	8,570,949	8,351,553	38,829,086	36,566,409	106,862,354	96,890,526
Non Current Liabilities										
Segmental Non Current Liabilities	1,279,180	1,085,211	4,558,681	4,594,257	96,605	58,647	286,590	440,498	6,221,056	6,178,613
Other Non-current Financial Liabilities	-	-	240	40	335	335	275,000	275,000	275,575	275,375
Deferred Tax Liability									4,094,685	3,473,577
Eliminations/Adjustments									(834,431)	-
Total Non Current Liabilities	1,279,180	1,085,211	4,558,921	4,594,297	96,940	58,982	561,590	715,498	9,756,885	9,927,565
Current Liabilities										
Segmental Current Liabilities	8,101,953	7,633,585	28,027,096	25,811,321	3,194,307	3,706,149	5,145,174	3,128,316	44,468,530	40,279,371
Income Tax Liability									1,692,826	1,440,936
Eliminations/Adjustments									(6,785,375)	(5,082,437)
Total Current Liabilities	8,101,953	7,633,585	28,027,096	25,811,321	3,194,307	3,706,149	5,145,174	3,128,316	39,375,981	36,637,870
Liabilities associated with assets held for sale	2,021	4,659							2,021	4,659
Total Liabilities	9,383,154	8,723,455	32,586,017	30,405,618	3,291,247	3,765,131	5,706,764	3,843,814	49,134,887	46,570,094
Total Segment Assets	38,994,874	33,934,165	59,887,916	54,815,450	8,570,949	8,351,553	38,829,085	36,566,409	146,282,824	133,667,577
Total Segment Liabilities	9,383,154	8,718,796	32,586,017	30,405,618	3,291,247	3,765,131	5,706,764	3,843,814	50,967,182	46,733,359
Other Segmental Information										
Acquisition Cost of Property Plant and Equipment	831,354	1,095,850	1,547,250	3,849,768	9,408	51,033	21,342	83,443	2,409,354	5,080,094
Depreciation and impairment of segmental assets	680,813	595,338	987,398	820,006	15,951	23,589	143,784	149,810	1,827,946	1,588,743
Provision for Employee Benefit Liability	117,417	119,210	154,107	154,361	6,316	12,501	21,711	17,239	299,552	303,311
Impairment/Amortization of Intangible Assets	19,150	15,867	96,004	44,690	104	170	6,504	8,539	121,762	69,266
Amortisation of Right-of-Use Assets	95,230	92,547	289,996	208,581	20,940	18,344	8,466	20,203	414,632	339,675

All values are in LKR'000, unless otherwise stated.
The above figures are provisional and subject to audit.

INVESTOR INFORMATION

	Three Months Ended 31 March	
	2026	2025
Market Value of Shares		
Closing Price on 31 March (LKR)	29.60	120.00
Last Traded Price on 31 March (LKR)	29.60	120.00
Highest Price During the Period (LKR)	36.00	128.00
Lowest Price During the Period (LKR)	27.60	102.75
Market Capitalisation on 31 March (LKR Mn)	88,681	71,677
Ratios		
Net Asset Per Share on 31 March (LKR)	19.03	16.67
Price Earnings Ratio on 31 March (Times)	9.93	8.90
Share Trading		
No of Transactions During the Period	25,390	9,456
No of Shares Traded During the Period	134,961,960	40,177,399
Value of Shares Traded During the Period (LKR. Mn)	4,482	4,598
Number of Shares*	2,995,985,015	597,307,400

*The share details for March 2026 are post share split.

NOTES TO THE FINANCIAL STATEMENTS

1 Basis of Preparation

The condensed interim financial statements have been prepared in accordance with Sri Lanka Accounting Standard LKAS- 34, Interim Financial Reporting. The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. Further, provisions of the Companies Act No. 7 of 2007 have been considered in preparing the interim financial statements.

Management is currently not aware of any material uncertainties that may cast significant doubt upon the Group's continuing performance.

2 Employee Share Option Scheme (ESOS)

(a) Employee Share Option Scheme (ESOS) - 2021

The Board of Directors, with the approval in principal of the Colombo Stock Exchange, and authorised by the shareholders at an Extraordinary General Meeting dated 30 June 2021, to create an Employee Share Option Scheme (ESOS) to offer 13,500,000 ordinary shares being 2.26% of the total issued and fully paid ordinary voting shares of the Company. The ESOS 2021 is applicable to Eligible Employees, who are employees of a company in the Hemas Group (i.e. the Company and subsidiaries of the Company as identified by the Board whose employees are eligible to participate in the Scheme)

The Grant Period under the ESOS 2021 shall commence on 20 July 2021 and end on 19 July 2026.

	Date Of Grant	No of Shares Granted	Grant Price (LKR)	Vesting Period	No of Shares Vested	Exercise Period
Grant 1	20.07.2021	3,538,112	82.46	1 Year	1,156,726	5 Years
Grant 2	20.07.2022	3,071,647	43.84	1 Year	927,454	5 Years
Grant 3	20.07.2023	3,375,000	71.02	1 Year	-	5 Years
Grant 4	01.10.2024	5,850,000	72.23	1 Year	5,600,000	5 Years
Grant 5	20.07.2025	5,000,000	29.79	1 Year	N/A	5 Years

Subsequent to the share split approved by the shareholders on 28 April 2025, the number of shares granted shall be multiplied by five, while the original exercise price shall be divided by five, in order to determine the post-split number of shares and the corresponding post-split exercise price.

Under the Group's Employee Share Option Scheme (ESOS), share options of the parent are granted to executives of the Group/ Company generally with more than 12 months of service. The exercise price of the share options is equal to the 30 day volume weighted average market price of the underlying shares on the date of grant. The share options vested after period of one year from the date of grant and it depends on the performance criteria and time criteria. The fair value of the share options is estimated at the grant date using the Black Scholes option pricing model taking into account the terms and conditions upon which the share options were granted.

There are no cash settlement alternatives. The Group does not have a past practice of cash settlement for these share options.

3 Events After The Reporting Date

The Board of Directors of the Company has declared a final dividend of LKR 0.75 per share for the financial year ended 31 March 2026 as required by section 56(2) of the companies Act No 07 of 2007 , the Board of Directors has confirmed that the Company satisfies the solvency test in accordance with section 57 of the companies Act No. 07 of 2007, and has obtained a certificate from the Auditors, prior to declaring the final dividend which is to be paid on or before 17 July 2026.

In accordance with the Sri Lanka Accounting Standard (LKAS 10) - Events after the reporting date, the final dividend has not been recognised as a liability in the Financial Statements as at 31 March 2026.

Other than those mention above, no circumstances have arisen since the reporting date, which would require adjustment to or disclosure in the financial statements.

4 There have been no significant changes in the nature of the contingent liabilities which were disclosed in the Audited Financial Statements for the year ended 31 March 2025.

SHARE INFORMATION

List of 20 Major Shareholders as at 31 March	2026		2025	
	No. of Shares*	%	No. of Shares	%
1 A Z Holdings (Pvt) Ltd.	470,461,525	15.70	94,092,305	15.75
2 Amagroup (Pvt) Ltd.	457,136,665	15.26	91,427,333	15.31
3 Saraz Investments (Pvt) Ltd.	447,826,385	14.95	89,565,277	14.99
4 Blueberry Investments (Pvt) Ltd.	444,639,700	14.84	88,927,940	14.89
5 Mr. E.D. Peiris	100,000,000	3.34	10,000,000	1.67
6 Employee's Provident Fund	94,752,933	3.16	-	-
7 Mrs. R.G. Abdulhussein	50,058,310	1.67	10,011,662	1.68
8 J.B. Cocoshell (Pvt) Ltd	44,953,808	1.50	9,195,571	1.54
9 BBH-Kopernik Global All Cap Fund	41,603,360	1.39	13,149,737	2.20
10 BBH-Tundra Sustainable Frontier Fund	35,009,640	1.17	7,001,928	1.17
11 BBH-Kopernik Global All Cap Equity Fund	30,705,975	1.02	8,677,203	1.45
12 BBH- Tundra Shikari Global	29,945,000	1.00	5,989,000	1.00
13 Rubber Investment Trust Ltd Account 1	28,035,990	0.94	8,145,002	1.36
14 Hatton National Bank PLC/ Phantom Investments (Private) Limited	26,944,305	0.90	-	-
15 Akbar Brothers (Pvt) Ltd	26,281,821	0.88	4,298,475	0.72
16 Mr. D.C. Fernando	16,344,480	0.55	-	-
17 Ranavav Holdings (Pvt) Ltd	15,560,397	0.52	3,408,035	0.57
18 Ceylon Investment PLC Account 2	14,933,595	0.50	3,706,719	0.62
19 Amana Bank PLC/Mr. Mohomed Nayaz Deen	12,596,305	0.42	-	-
20 Deutsche Bank as a Trustee for JB Vantage Value Equity Fund	12,193,436	0.41	3,280,622	0.55

Directors' Shareholding as at 31 March	2026	2025
	No. of Shares*	No. of Shares
DIRECTORS' INDIRECT SHAREHOLDING		
A Z Holdings (Pvt) Ltd.	470,461,525	94,092,305
Amagroup (Pvt) Ltd.	457,136,665	91,427,333
Saraz Investments (Pvt) Ltd.	447,826,385	89,565,277
Blueberry Investments (Pvt) Ltd.	444,639,700	88,927,940
DIRECTORS' DIRECT SHAREHOLDING		
Mr. A. Fernando (Chairman)	-	-
Mr. M. A. H. Esufally (Deputy Chairman)	2,913,165	582,633
Mr. A. Chandra (Group CEO)	-	-
Mr. A. N. Esufally	86,765	17,353
Mr. I. A. H. Esufally	431,420	86,284
Mr. R. P. Pathirana	-	-
Mr. S. Weerasinghe	-	-
Ms. T. Perera	-	-
	1,823,495,625	364,699,125

Public Holding as at 31 March	2026*	2025
Issued Share Capital (No. of Shares)	2,995,985,015	597,307,400
Public Holding as a % of Issued Share Capital	37.55%	36.84%
Total Number of Shareholders	18,228	7,853
Number of Shareholders representing the Public Holding	18,215	7,836

Minimum Public Holding Requirement as per Listing Rules 7.13.1

	Float Adjusted Market Capitalisation - (LKR)	Public Holding Percentage	No of Shareholders	Option
Minimum Public Holding as at 31 March 2026	33,298,000,622	37.55%	18,215	1

*The share details for March 2026 are post share split.

CORPORATE INFORMATION

Legal Form

A limited Liability Company incorporated in Sri Lanka and listed on the Colombo Stock Exchange on 15th October 2003.

Date of Incorporation

10 December 1948

Date of Registration

30 May 2007

Company Registration Number

PQ 6

Accounting year end

31 March

Registered Office

Hemas House
No. 75, Braybrooke Place,
Colombo 2.

Website

www.hemas.com

Telephone

+ 94 11 4731731

Auditors

Ernst & Young
Chartered Accountants
Rotunda Towers, No.109, Galle Road, P.O. Box 101, Colombo 03.

Directors

Mr. A. Fernando (Chairman)
Mr. M. A. H. Esufally (Deputy Chairman)
Mr. A. Chandra (Group CEO)
Mr. A. N. Esufally
Mr. I. A. H. Esufally
Mr. R. P. Pathirana
Mr. S. Weerasinghe
Ms. T. Perera

Secretaries

Hemas Corporate Services (Pvt) Ltd.
'Hemas House' No. 75, Braybrooke Place, Colombo 2
Telephone: +94 11 4731731 (hunting)
Facsimile: +94 11 4731777

Registrars

SSP Corporate Services (Pvt) Ltd.
No. 101, Inner Flower Road, Colombo 03.
Telephone: +94 11 2573894, +94 11 2576871
Email: sssec@sltnet.lk

Lawyers to the Company

Group Legal
Hemas Holdings PLC
'Hemas House' No. 75, Braybrooke Place, Colombo 2
Telephone: +94 11 4731731

Investor Relations

Hemas Holdings PLC
'Hemas House' No. 75, Braybrooke Place, Colombo 2
Telephone: +94 11 4731731
Email: ir@hemas.com

Bankers

Bank of Ceylon
Citi Bank N.A.
Commercial Bank of Ceylon PLC
Deutsche Bank AG
DFCC Bank PLC
Hatton National Bank PLC
National Development Bank PLC
Nations Trust Bank PLC
People's Bank
Sampath Bank PLC
Standard Chartered Bank
Seylan Bank PLC
The Hongkong & Shanghai Banking Corp. Ltd.
Union Bank PLC